全文获取类型
收费全文 | 1018篇 |
免费 | 68篇 |
国内免费 | 39篇 |
专业分类
耳鼻咽喉 | 20篇 |
儿科学 | 39篇 |
妇产科学 | 21篇 |
基础医学 | 171篇 |
口腔科学 | 20篇 |
临床医学 | 85篇 |
内科学 | 196篇 |
皮肤病学 | 17篇 |
神经病学 | 55篇 |
特种医学 | 171篇 |
外科学 | 43篇 |
综合类 | 16篇 |
一般理论 | 1篇 |
预防医学 | 34篇 |
眼科学 | 11篇 |
药学 | 145篇 |
肿瘤学 | 80篇 |
出版年
2023年 | 2篇 |
2022年 | 4篇 |
2021年 | 7篇 |
2020年 | 6篇 |
2019年 | 10篇 |
2018年 | 12篇 |
2017年 | 11篇 |
2016年 | 11篇 |
2015年 | 17篇 |
2014年 | 19篇 |
2013年 | 23篇 |
2012年 | 24篇 |
2011年 | 23篇 |
2010年 | 24篇 |
2009年 | 35篇 |
2008年 | 23篇 |
2007年 | 45篇 |
2006年 | 32篇 |
2005年 | 24篇 |
2004年 | 26篇 |
2003年 | 22篇 |
2002年 | 25篇 |
2001年 | 25篇 |
2000年 | 17篇 |
1999年 | 25篇 |
1998年 | 61篇 |
1997年 | 49篇 |
1996年 | 45篇 |
1995年 | 37篇 |
1994年 | 32篇 |
1993年 | 46篇 |
1992年 | 25篇 |
1991年 | 35篇 |
1990年 | 27篇 |
1989年 | 38篇 |
1988年 | 28篇 |
1987年 | 31篇 |
1986年 | 19篇 |
1985年 | 31篇 |
1984年 | 17篇 |
1983年 | 21篇 |
1982年 | 18篇 |
1981年 | 19篇 |
1980年 | 20篇 |
1979年 | 3篇 |
1978年 | 9篇 |
1977年 | 8篇 |
1976年 | 7篇 |
1975年 | 6篇 |
1973年 | 1篇 |
排序方式: 共有1125条查询结果,搜索用时 0 毫秒
121.
122.
Drug-induced thrombocytopenia is associated with increased binding of IgG to platelets both in vivo and in vitro 总被引:3,自引:0,他引:3
Kelton JG; Meltzer D; Moore J; Giles AR; Wilson WE; Barr R; Hirsh J; Neame PB; Powers PJ; Walker I; Bianchi F; Carter CJ 《Blood》1981,58(3):524-529
Thrombocytopenia is a common serious adverse effect of drug treatment. A variety of in vitro diagnostic techniques to confirm the diagnosis are available, but the majority lack sufficient sensitivity to detect all cases of drug-induced thrombocytopenia. We studied 19 patients with suspected drug-induced thrombocytopenia and demonstrated that platelet- associated IgG (PAIgG) was elevated in all at the time of thrombocytopenia, and PAIgG returned to normal levels as the thrombocytopenia resolved. In the majority of patients, the platelet count rapidly returned to normal after the drug was discontinued; however, in six patients, the thrombocytopenia persisted well beyond the period of time that the offending drug would be expected to be cleared from the blood. In 13 patients, serum obtained after recovery was used to identify the drug responsible for the thrombocytopenia in an in vitro assay. In all cases, the addition of the drug historically associated with the thrombocytopenic episode was associated with an increased binding of IgG to control platelets. For uncertain reasons, the concentration of drug required to increase the in vitro binding of IgG to test platelets was often more than the concentration usually achieved in vivo. Wider application of these techniques may provide better understanding of the clinical characteristics and mechanisms responsible for drug-induce thrombocytopenia. 相似文献
123.
A unique, intrinsic, hereditary canine platelet disorder attributable to abnormal fibrinogen receptor availability is described. Thrombopathic platelets from 13 severely affected basset hounds failed to aggregate in response to all agonists tested except thrombin. Normal platelet interaction with the various stimuli was inferred on the basis of their ability to elicit unimpaired shape change in thrombopathic platelets. No quantitative differences in major platelet membrane glycoproteins, intraplatelet fibrinogen, adenine nucleotides, or serotonin uptake were detected. Dense granule secretion was impaired. The ultrastructural appearance of thrombopathic platelets was normal. Fibrinogen-platelet interaction was evaluated by reacting platelet-rich plasma (PRP) with fibrinogen coupled to polymeric acrylonitrile beads and scoring the extent of stimulus-induced agglutination. The aggregatory responses of normal and thrombopathic platelets were closely correlated with fibrinogen receptor availability. In contrast to human platelets, epinephrine-stimulated canine platelets did not interact with immobilized fibrinogen, and arachidonate generally induced only weak agglutination. Thrombopathic platelets agglutinated fibrinogen beads at reduced rates when stimulated with physiologic doses of thrombin and high-dose calcium ionophore, A23187. Our data suggest that thrombin-mediated induction of canine platelet fibrinogen receptors may proceed by pathway(s) alternate to those shared by other platelet agonists, and/or that secreted granule constituents may act synergistically with thrombin to overcome inhibition of signal-response- coupled reactions mediating the interaction of fibrinogen with its receptor. This congenital platelet defect provides further evidence, in a species other than human, for the pivotal role of fibrinogen receptor induction in platelet aggregation. 相似文献
124.
Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia 总被引:2,自引:4,他引:2
Rabinowe SN; Soiffer RJ; Gribben JG; Daley H; Freedman AS; Daley J; Pesek K; Neuberg D; Pinkus G; Leavitt PR 《Blood》1993,82(4):1366-1376
Twenty patients with poor prognosis B-cell chronic lymphocytic leukemia (B-CLL) underwent uniform high-dose chemoradiotherapy followed by rescue with multiple monoclonal antibody-purged autologous bone marrow (BM) (12 patients) or T-cell-depleted allogeneic BM from HLA-identical siblings (8 patients) in a pilot study to assess the feasibility of BM transplantation (BMT) in this disease. All had poor prognosis disease by either staging, BM pattern, tumor doubling time criteria, or cytogenetics. All patients achieved remission criteria (defined as < or = 2 adenopathy, absence of splenomegaly, < or = 20% of the intertrabecular space involved on BM biopsy) before BMT. Despite the use of fludarabine, a median of three treatment regimens were required to achieve BMT eligibility. After BMT, all patients achieved complete hematologic engraftment. Toxicities were not significantly different between autologous versus allogeneic BMT. Two toxic deaths were observed. Of 19 evaluable patients, 17 clinical complete clinical remissions (89%) were observed, with 2 patients (1 allogeneic and 1 autologous) exhibiting persistent BM disease. Complete clinical remissions were documented at the phenotypic and molecular level for the majority of patients in whom dual fluorescence for CD5 and CD20 (15 of 15; 100%) and Ig gene rearrangements (11 of 14; 79%) were performed. Although long-term follow-up is needed to assess any potential impact on the disease-free and overall survival of these patients, this study shows the feasibility of using high-dose chemoradiotherapy and BMT in patients with poor prognosis B-CLL. 相似文献
125.
H.Pyloriinfectshalf0ftheworldp0pulationandtheprevalencevarieswidelyindifferentpartsoftheworldwithaverageratesof4O%-50%inwesterncountries,risingtomorethan90%inthedevel0pingworld[1l2.Compellingevidencefromepidemiol0gicalandhistopathologicalstudieshaslinkedH.Pyloriinfectiont0thesubsequentdevelopmentofgastriccarcinogenesisL'].Furthermore,Watanabeandcolleaguesrecentlyinducedgastricadenocarcinomain37%oforallyinfectedM0ngoliangerbils,whichwereprecededwithaseriesofpremalignantchangesingastricmucosao… 相似文献
126.
High molecular weight kininogen: localization in the unstimulated and activated platelet and activation by a platelet calpain(s) 总被引:5,自引:0,他引:5
High mol wt kininogen (HMWK), the major cofactor-substrate of the contact phase of coagulation, is contained within and secreted by platelets. Studies have been performed to localize platelet HMWK in both the unstimulated and activated platelet and to ascertain the effect of platelet enzymes on HMWK itself. On platelet subcellular fractionation, platelet HMWK was localized to alpha-granules, and platelets from a patient with a deficiency of these granules (gray platelet syndrome) had 28% normal platelet HMWK. Platelet HMWK, in addition to being secreted from the platelet, was also localized to the surface of the platelet when activated. Using a competitive enzyme- linked immunosorbent assay for HMWK as an indirect antibody consumption assay, the external membrane of thrombin-activated platelets as well as the releasate from these stimulated platelets had 17 ng HMWK antigen/10(8) platelets available, whereas unstimulated platelets and their supernatant had only 4.9 and 4.2 ng HMWK/10(8) platelets present, respectively. The anti-HMWK antibody consumption by activated normal platelets was specific for membrane-expressed platelet HMWK, since activated platelets from a patient with total kininogen deficiency did not adsorb the anti-HMWK antibody. Enzymes in the cytosolic fraction of platelets cleaved 125I-HMWK (mol wt 120,000) into a mol wt 100,000 polypeptide as well as smaller products at mol wt 74,000, mol wt 62,000, mol wt 47,000, and a few components below mol wt 45,000. No cleavage products were observed when DFP and leupeptin were present. The cleavage of HMWK was specifically prevented by inhibitors of calcium-activated cysteine proteases (leupeptin, N-ethylmaleimide, iodoacetamide, and EDTA) but not by inhibitors of serine proteases (DFP, benzamidine, soybean trypsin inhibitor, or aprotinin). Platelet cytosol increased the coagulant activity of exogenous purified HMWK with maximum HMWK coagulant activity (35-fold) occurring within ten minutes of exposure to platelet cytosol. Treatment of platelet cytosol with leupeptin prevented the increase in the coagulant activity of exogenous HMWK. These studies indicate that activated platelets express platelet HMWK on their external membrane and platelet enzymes can cleave and increase the coagulant activity of exogenous HMWK. 相似文献
127.
T. Suormala V. T. Ramaekers S. Schweitzer B. Fowler M. C. Laub C. Schwermer J. Bachmann E. R. Baumgartner 《Journal of inherited metabolic disease》1995,18(6):689-700
Summary We describe a simple method for the detection of biotinidaseK
m-variants and detailed biochemical investigations in 5 such patient. They were detected among 103 patients with plasma biotinidase
activity which ranged from undetectable to 30% of the mean normal value. Two different types of biotinidaseK
m-variants were found. (1) In 3 infants biotinidase had a single 105–430-fold elevatedK
m for biocytin. Biotinidase showed very low activities (0.2–4% of the mean normal value) in the routine colorimetric assay
and was not functionalin vivo. Accordingly, these patients presented with classical clinical illness. (2) In two patients biotinidase showed biphasic kinetics
indicating the presence of one component with a normalK
m and reducedV
max (1.7% and 12%), and another with 330- and 59-fold elevatedK
m, respectively. In these two patients, biotinidase proved to be at least partially functionalin vivo. However, the first patient developed severe symptoms and biotin deficiency late, at the age of 10–15 years, and the second
had marginal biotin deficiency at the age of 2 years but no clinical symptoms. Comparative studies revealed that both patients
had more severe biotin deficiency than age-matched patients with similar levels of residual biotinidase activity and a single
normalK
m. Therefore, all patients with residual biotinidase activity should be evaluated for the presence of aK
m-mutation, since such patients should be treated with biotin. These can easily be detected by including a second substrate
concentration (1.5 mmol/L) in the routine colorimetric biotinidase assay which is performed with 0.15 mmol/L biotin. Increased
activity with the higher substrate concentration indicates the presence of aK
m-mutation. Detailed kinetic studies are needed to evaluate the distinct forms ofK
m-variants. 相似文献
128.
129.
High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission 总被引:14,自引:9,他引:14
Freedman AS; Gribben JG; Neuberg D; Mauch P; Soiffer RJ; Anderson KC; Pandite L; Robertson MJ; Kroon M; Ritz J; Nadler LM 《Blood》1996,88(7):2780-2786
We report the results of a study in previously untreated advanced stage patients with follicular lymphoma (FL) who underwent uniform induction chemotherapy with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) followed by myeloablative therapy and anti-B-cell monoclonal antibody purged autologous bone marrow transplantation (ABMT). Eighty-three patients with previously untreated, low-grade FL were enrolled. After CHOP induction, only 36% achieved complete remission (CR) and 77 patients underwent ABMT. Before BM harvest, 70 patients had a known t(14;18), as determined by polymerase chain reaction (PCR), and all remained PCR positive in the BM at harvest. After ABMT, the disease-free survival (DFS) and overall survival are estimated to be 63% and 89% at 3 years, respectively, with a median follow-up of 45 months. Patients whose BM was PCR negative after purging experienced significantly longer freedom from recurrence (FFR) than those whose BM remained PCR positive (P = .0006). Continued PCR negativity in follow-up BM samples was also strongly predictive of continued CR. This study suggests that a subset of patients with advanced FL may experience prolonged clinical and molecular remissions following high-dose ablative therapy, although longer follow-up will be necessary to determine potential impact on overall survival. 相似文献
130.
Hans Van Brabandt Cécile Camberlin France Vrijens Yves Parmentier Dirk Ramaekers Luc Bonneux 《European heart journal》2006,27(22):2649-2654
AIMS: To assess the outcome and costs of patients with acute myocardial infarction (AMI) after initial admission to hospitals with or without catheterization facilities in Belgium. METHODS AND RESULTS: From a nationwide hospital register, we retrieved the data of 34 961 patients discharged during 1999-2001 with a principal diagnosis of AMI. They were initially admitted to hospitals without catheterization facilities (A), with diagnostic (B1) or interventional catheterization facilities (B2). Mortality has been recorded till the end of 2003 and re-admissions till the end of 2001. The mortality hazard ratio and 95% CI of 5 years mortality of A vs. B2 was 1.01 (0.97, 1.06) and of B1 vs. B2 was 1.03 (0.98, 1.09). Re-admission rates and 95% CI for cardiovascular reason per 100 patient-years were 23.5 (22.7, 24.3) for A, 23.8 (22.5, 25.1) for B1, and 22.0 (21.2, 22.9) for B2. The mean cost in hospital of a patient at low risk with a single stay was in A 4072 euro (median: 3,861; IQR: 4467-3476), in B1 5083 euro (median: 5153; IQR: 5769-4340), and in B2 7741 euro (median: 7553; IQR: 8211-7298). CONCLUSION: Services with catheterization facilities compared with services without them showed no better health outcomes, but delivered more expensive care. 相似文献